ClinicalTrials.gov
public full text
Public Domain
FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression
Estimate the maximum tolerated dose and/or recommended phase II dose and efficacy of FGF401 as single agent and in combination with PDR001 in patients with hepatocellular carcinoma and as single agent in patients with other solid malignancies based on RECIST 1.1.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study of IMM-101 in Combination With Radiation Induced Tumour Necrosis in Colorectal Cancer#1350934
- Enhanced CT‑based radiomics model to predict CD40LG expression and clinical prognosis in head and neck squamous cell carcinoma.#122807
- A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors#903872
- Liver Cancer and Immunotherapy in the Liquid Biopsy Era#208450
- Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements#915381
Record · ID 1186257
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive